Effectiveness of JN.1 monovalent COVID-19 vaccination in EU/EEA countries between October 2024 and January 2025: a VEBIS electronic health record network study

IF 4.5 3区医学 Q2 IMMUNOLOGY

Vaccine Pub Date : 2025-09-19 DOI:10.1016/j.vaccine.2025.127752

James Humphreys , Alexandre Blake , Nathalie Nicolay , Toon Braeye , Izaak Van Evercooren , Christian Holm Hansen , Ida Rask Moustsen-Helms , Chiara Sacco , Alberto Mateo-Urdiales , Jesús Castilla , Iván Martínez-Baz , Ausenda Machado , Andre Brito , Rickard Ljung , Nicklas Pihlstrom , Yohann Mansiaux , Susana Monge , Sabrina Bacci , Baltazar Nunes , VEBIS-EHR working group

{"title":"Effectiveness of JN.1 monovalent COVID-19 vaccination in EU/EEA countries between October 2024 and January 2025: a VEBIS electronic health record network study","authors":"James Humphreys , Alexandre Blake , Nathalie Nicolay , Toon Braeye , Izaak Van Evercooren , Christian Holm Hansen , Ida Rask Moustsen-Helms , Chiara Sacco , Alberto Mateo-Urdiales , Jesús Castilla , Iván Martínez-Baz , Ausenda Machado , Andre Brito , Rickard Ljung , Nicklas Pihlstrom , Yohann Mansiaux , Susana Monge , Sabrina Bacci , Baltazar Nunes , VEBIS-EHR working group","doi":"10.1016/j.vaccine.2025.127752","DOIUrl":null,"url":null,"abstract":"<div><div>We estimated vaccine effectiveness (VE) of Omicron JN.1-adapted COVID-19 vaccines administered during the 2024 autumnal vaccination campaign against COVID-19 hospitalisation and death among eligible individuals aged ≥65 years. The study period was October 2024–January 2025. Using a common protocol across six EU/EEA study sites, we linked electronic health records to construct retrospective cohorts and applied Cox modelling to estimate VE via confounder-adjusted hazard ratios.</div><div>The majority of vaccines administered during the study period were Omicron JN.1-adapted COVID-19 vaccines (99 %). VE against hospitalisation was 60 % (95 % Confidence Interval: 48–70 %) and against COVID-19-related death was 78 % (95 %CI: 64–87 %) among individuals aged 65–79 years; 58 % (95 %CI: 48–66 %) and 62 % (95 %CI: 32–79 %) among those aged ≥80 years.</div><div>These results indicate high effectiveness in the initial months of the campaign. Continued monitoring is necessary to confirm these results, including estimates of VE in those with longer time since vaccination and during different variant predominance periods.</div></div>","PeriodicalId":23491,"journal":{"name":"Vaccine","volume":"64 ","pages":"Article 127752"},"PeriodicalIF":4.5000,"publicationDate":"2025-09-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Vaccine","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0264410X25010497","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"IMMUNOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

We estimated vaccine effectiveness (VE) of Omicron JN.1-adapted COVID-19 vaccines administered during the 2024 autumnal vaccination campaign against COVID-19 hospitalisation and death among eligible individuals aged ≥65 years. The study period was October 2024–January 2025. Using a common protocol across six EU/EEA study sites, we linked electronic health records to construct retrospective cohorts and applied Cox modelling to estimate VE via confounder-adjusted hazard ratios.

The majority of vaccines administered during the study period were Omicron JN.1-adapted COVID-19 vaccines (99 %). VE against hospitalisation was 60 % (95 % Confidence Interval: 48–70 %) and against COVID-19-related death was 78 % (95 %CI: 64–87 %) among individuals aged 65–79 years; 58 % (95 %CI: 48–66 %) and 62 % (95 %CI: 32–79 %) among those aged ≥80 years.

These results indicate high effectiveness in the initial months of the campaign. Continued monitoring is necessary to confirm these results, including estimates of VE in those with longer time since vaccination and during different variant predominance periods.

查看原文本刊更多论文

2024年10月至2025年1月期间欧盟/欧洲经济区国家JN.1单价COVID-19疫苗接种的有效性：一项VEBIS电子健康记录网络研究

我们估计了2024年秋季针对年龄≥65岁的符合条件个体的COVID-19住院和死亡的疫苗接种运动中使用的Omicron jn .1适应的COVID-19疫苗的疫苗有效性（VE）。研究时间为2024年10月至2025年1月。我们在6个EU/EEA研究地点使用了通用协议，将电子健康记录联系起来构建回顾性队列，并应用Cox模型通过混杂因素调整风险比来估计VE。在研究期间接种的大多数疫苗是Omicron jn .1适应的COVID-19疫苗（99%）。在65-79岁的个体中，反对住院治疗的VE为60%(95%置信区间：48- 70%)，反对covid -19相关死亡的VE为78%(95%置信区间：64- 87%)；年龄≥80岁的患者分别为58% （95% CI: 48 ~ 66%）和62% （95% CI: 32 ~ 79%）。这些结果表明，该运动在最初几个月的成效很高。需要继续监测以确认这些结果，包括接种疫苗后较长时间和不同变异优势期的VE估计。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Vaccine 医学-免疫学

CiteScore

8.70

自引率

5.50%

发文量

992

审稿时长

131 days

期刊介绍： Vaccine is unique in publishing the highest quality science across all disciplines relevant to the field of vaccinology - all original article submissions across basic and clinical research, vaccine manufacturing, history, public policy, behavioral science and ethics, social sciences, safety, and many other related areas are welcomed. The submission categories as given in the Guide for Authors indicate where we receive the most papers. Papers outside these major areas are also welcome and authors are encouraged to contact us with specific questions.